✦ LIBER ✦

Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 (‘Iressa’)

✍ Scribed by Sewell, J M; Macleod, K G; Ritchie, A; Smyth, J F; Langdon, S P

Book ID: 109997119
Publisher: Nature Publishing Group
Year: 2002
Tongue: English
Weight: 166 KB
Volume: 86
Category: Article
ISSN: 0007-0920
DOI: 10.1038/sj.bjc.6600058

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Radiosensitivity of Tumor Cell Lines aft

Radiosensitivity of Tumor Cell Lines after Pretreatment with the EGFR Tyrosine Kinase Inhibitor ZD1839 (Iressa®)

✍ Susanne Burdak-Rothkamm; Claudia E. Rübe; Tan Phu Nguyen; Daniela Ludwig; Klaus 📂 Article 📅 2005 🏛 Springer 🌐 German ⚖ 399 KB

Differential radiosensitisation by ZD183

Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines

✍ Maddineni, S B; Sangar, V K; Hendry, J H; Margison, G P; Clarke, N W 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 141 KB

ChemInform Abstract: Studies Leading to

ChemInform Abstract: Studies Leading to the Identification of ZD1839 (Iressa): An Orally Active, Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Targeted to the Treatment of Cancer.

✍ Keith H. Gibson; et al. et al. 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 29 KB 👁 2 views

Targeted inhibition of the epidermal gro

Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 (‘Iressa’) induces cell-cycle arrest and inhibits proliferation in prostate cancer cells

✍ Alessandro Sgambato; Andrea Camerini; Beatrice Faraglia; Raffaele Ardito; Gabrie 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 297 KB 👁 2 views

## Abstract The epidermal growth factor (EGF) plays a role in the development of prostate cancer, which becomes essential after androgen resistance has emerged. The EGF receptor (EGFR) is therefore a potential target for anticancer therapy. We evaluated the effects of ZD1839 (‘Iressa’), an orally a

Ocular findings in patients with solid t

Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Phase I and II clinical trials

✍ Murray, P I; Bristow, E; Forsythe, B J; Faulkner, K; Tullo, A B; Esmaeli, B 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 187 KB

ZD1839 (Iressa), a novel epidermal growt

ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression

✍ Neil G. Anderson; Tawhid Ahmad; Kai Chan; Richard Dobson; Nigel J. Bundred 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 192 KB 👁 1 views

Overexpression of the growth factor receptors EGFR and erbB2 occurs frequently in several human cancers and is associated with aggressive tumour behaviour and poor patient prognosis. We have investigated the effects of ZD1839 (Iressa), a novel EGFR tyrosine kinase inhibitor, on the growth, in vitro